471 related articles for article (PubMed ID: 23136553)
1. Interleukin-6--a key regulator of colorectal cancer development.
Waldner MJ; Foersch S; Neurath MF
Int J Biol Sci; 2012; 8(9):1248-53. PubMed ID: 23136553
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6 trans-signaling in inflammatory bowel disease.
Mitsuyama K; Sata M; Rose-John S
Cytokine Growth Factor Rev; 2006 Dec; 17(6):451-61. PubMed ID: 17045835
[TBL] [Abstract][Full Text] [Related]
3. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6.
Rose-John S
Int J Biol Sci; 2012; 8(9):1237-47. PubMed ID: 23136552
[TBL] [Abstract][Full Text] [Related]
4. Aspirin promotes apoptosis in a murine model of colorectal cancer by mechanisms involving downregulation of IL-6-STAT3 signaling pathway.
Tian Y; Ye Y; Gao W; Chen H; Song T; Wang D; Mao X; Ren C
Int J Colorectal Dis; 2011 Jan; 26(1):13-22. PubMed ID: 20886344
[TBL] [Abstract][Full Text] [Related]
5. IL-6 signaling promotes tumor growth in colorectal cancer.
Becker C; Fantini MC; Wirtz S; Nikolaev A; Lehr HA; Galle PR; Rose-John S; Neurath MF
Cell Cycle; 2005 Feb; 4(2):217-20. PubMed ID: 15655344
[TBL] [Abstract][Full Text] [Related]
6. Dual signaling role of the protein tyrosine phosphatase SHP-2 in regulating expression of acute-phase plasma proteins by interleukin-6 cytokine receptors in hepatic cells.
Kim H; Baumann H
Mol Cell Biol; 1999 Aug; 19(8):5326-38. PubMed ID: 10409724
[TBL] [Abstract][Full Text] [Related]
7. Growth-suppressive activity of raloxifene on liver cancer cells by targeting IL-6/GP130 signaling.
Wang Y; Ma H; Zhao C; Liu T; Yan D; Jou D; Li H; Zhang C; Lü J; Li C; Lin J; Li S; Lin L
Oncotarget; 2017 May; 8(20):33683-33693. PubMed ID: 28430601
[TBL] [Abstract][Full Text] [Related]
8. RKIP phosphorylation and STAT3 activation is inhibited by oxaliplatin and camptothecin and are associated with poor prognosis in stage II colon cancer patients.
Cross-Knorr S; Lu S; Perez K; Guevara S; Brilliant K; Pisano C; Quesenberry PJ; Resnick MB; Chatterjee D
BMC Cancer; 2013 Oct; 13():463. PubMed ID: 24098947
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic strategies for targeting the IL-6/STAT3 cytokine signaling pathway in inflammatory bowel disease.
Mitsuyama K; Matsumoto S; Masuda J; Yamasakii H; Kuwaki K; Takedatsu H; Sata M
Anticancer Res; 2007; 27(6A):3749-56. PubMed ID: 17970038
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease.
Rose-John S; Mitsuyama K; Matsumoto S; Thaiss WM; Scheller J
Curr Pharm Des; 2009; 15(18):2095-103. PubMed ID: 19519447
[TBL] [Abstract][Full Text] [Related]
11. STAT3 and sphingosine-1-phosphate in inflammation-associated colorectal cancer.
Nguyen AV; Wu YY; Lin EY
World J Gastroenterol; 2014 Aug; 20(30):10279-87. PubMed ID: 25132744
[TBL] [Abstract][Full Text] [Related]
12. Synthetic antiprotozoal thiazolide drug induced apoptosis in colorectal cancer cells: implications of IL-6/JAK2/STAT3 and p53/caspases-dependent signaling pathways based on molecular docking and in vitro study.
Tantawy MA; El-Sherbeeny NA; Helmi N; Alazragi R; Salem N; Elaidy SM
Mol Cell Biochem; 2020 Jun; 469(1-2):143-157. PubMed ID: 32356241
[TBL] [Abstract][Full Text] [Related]
13. The IL-6/JAK/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer (Review).
Wang SW; Sun YM
Int J Oncol; 2014 Apr; 44(4):1032-40. PubMed ID: 24430672
[TBL] [Abstract][Full Text] [Related]
14. Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development.
Waldner MJ; Neurath MF
Semin Immunol; 2014 Feb; 26(1):75-9. PubMed ID: 24447345
[TBL] [Abstract][Full Text] [Related]
15. Bazedoxifene exhibits growth suppressive activity by targeting interleukin-6/glycoprotein 130/signal transducer and activator of transcription 3 signaling in hepatocellular carcinoma.
Ma H; Yan D; Wang Y; Shi W; Liu T; Zhao C; Huo S; Duan J; Tao J; Zhai M; Luo P; Guo J; Tian L; Mageta L; Jou D; Zhang C; Li C; Lin J; Lv J; Li S; Lin L
Cancer Sci; 2019 Mar; 110(3):950-961. PubMed ID: 30648776
[TBL] [Abstract][Full Text] [Related]
16. Ginsenoside 20(S)-Rh2 exerts anti-cancer activity through targeting IL-6-induced JAK2/STAT3 pathway in human colorectal cancer cells.
Han S; Jeong AJ; Yang H; Bin Kang K; Lee H; Yi EH; Kim BH; Cho CH; Chung JW; Sung SH; Ye SK
J Ethnopharmacol; 2016 Dec; 194():83-90. PubMed ID: 27566200
[TBL] [Abstract][Full Text] [Related]
17. The effectiveness of an anti-human IL-6 receptor monoclonal antibody combined with chemotherapy to target colon cancer stem-like cells.
Ying J; Tsujii M; Kondo J; Hayashi Y; Kato M; Akasaka T; Inoue T; Shiraishi E; Inoue T; Hiyama S; Tsujii Y; Maekawa A; Kawai S; Fujinaga T; Araki M; Shinzaki S; Watabe K; Nishida T; Iijima H; Takehara T
Int J Oncol; 2015 Apr; 46(4):1551-9. PubMed ID: 25625841
[TBL] [Abstract][Full Text] [Related]
18. Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling.
Sanchez-Lopez E; Flashner-Abramson E; Shalapour S; Zhong Z; Taniguchi K; Levitzki A; Karin M
Oncogene; 2016 May; 35(20):2634-44. PubMed ID: 26364612
[TBL] [Abstract][Full Text] [Related]
19. Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma.
Gordziel C; Bratsch J; Moriggl R; Knösel T; Friedrich K
Br J Cancer; 2013 Jul; 109(1):138-46. PubMed ID: 23756862
[TBL] [Abstract][Full Text] [Related]
20. Response to IL-6 trans- and IL-6 classic signalling is determined by the ratio of the IL-6 receptor α to gp130 expression: fusing experimental insights and dynamic modelling.
Reeh H; Rudolph N; Billing U; Christen H; Streif S; Bullinger E; Schliemann-Bullinger M; Findeisen R; Schaper F; Huber HJ; Dittrich A
Cell Commun Signal; 2019 May; 17(1):46. PubMed ID: 31101051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
